Home » QLT'S PROSTATE DRUG SHOWN TO BE INEFFECTIVE IN TRIAL
QLT'S PROSTATE DRUG SHOWN TO BE INEFFECTIVE IN TRIAL
QLT has reported that a Phase II clinical trial of lemuteporfin-injectable in patients with benign prostatic hyperplasia (BPH) did not meet the study's primary efficacy objective at three months.
While the decrease in the American Urological Association-symptom score was consistent with that seen after other minimally invasive therapies there was no significant difference between treatment and sham-control groups, the company said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May